Abstract:Hemorrhagic fever with renal syndrome (HFRS) occurs widely throughout Eurasia. Unfortunately, there is no effective treatment, and prophylaxis remains the best option against the major pathogenic agent, hantaan virus (HTNV), which is an Old World hantavirus. However, the absence of cellular immune responses and immunological memory hampers acceptance of the current inactivated HFRS vaccine. Previous studies revealed that a lysosome-associated membrane protein 1 (LAMP1)-targeting strategy involving a DNA vaccine based on the HTNV glycoprotein Gn successfully conferred long-term immunity, and indicated that further research on Gc, another HTNV antigen, was warranted. Plasmids encoding Gc and lysosome-targeted Gc, designated pVAX-Gc and pVAX-LAMP/Gc, respectively, were constructed. Proteins of interest were identified by fluorescence microscopy following cell line transfection. Five groups of 20 female BALB/c mice were subjected to the following inoculations: inactivated HTNV vaccine, pVAX-LAMP/Gc, pVAX-Gc, and, as the negative controls, pVAX-LAMP or the blank vector pVAX1. Humoral and cellular immunity were assessed by enzyme-linked immunosorbent assays (ELISAs) and 15-mer peptide enzyme-linked immunospot (ELISpot) epitope mapping assays. Repeated immunization with pVAX-LAMP/Gc enhanced adaptive immune responses, as demonstrated by the specific and neutralizing antibody titers and increased IFN-γ production. The inactivated vaccine induced a comparable humoral reaction, but the negative controls only elicited insignificant responses. Using a mouse model of HTNV challenge, the in vivo protection conferred by the inactivated vaccine and Gc-based constructs (with/without LAMP recombination) was confirmed. Evidence of pan-epitope reactions highlighted the long-term cellular response to the LAMP-targeting strategy, and histological observations indicated the safety of the LAMP-targeting vaccines. The long-term protective immune responses induced by pVAX-LAMP/Gc may be due to the advantage afforded by lysosomal targeting after exogenous antigen processing initiation and major histocompatibility complex (MHC) class II antigen presentation trafficking. MHC II-restricted antigen recognition effectively primes HTNV-specific CD4+ T-cells, leading to the promotion of significant immune responses and immunological memory. An epitope-spreading phenomenon was observed, which mirrors the previous result from the Gn study, in which the dominant IFN-γ-responsive hot-spot epitopes were shared between HLA-II and H2d. Importantly, the pan-epitope reaction to Gc indicated that Gc should be with potential for use in further hantavirus DNA vaccine investigations.

Production and Characterization of A Recombinant Single-Chain Antibody Against Hantaan Virus Envelop Glycoprotein

Study on the Recombinant Expression of Hantaan Virus Protein N and the Establishment and Application of Rnp-Igm Direct Capture ELISA

Construction and identification of prokaryotic and eukaryotic expression vectors of ScFv-Cκ of monoclonal antibody against Hantaanvirus NP antigen

Construction and Evaluation of DNA Vaccine Encoding Hantavirus Glycoprotein N-terminal Fused with Lysosome-Associated Membrane Protein.

[Transient Expression and Characterization of Intracellular Single Chain Fv Against the Nucleocapsid Protein of Hantavirus].

Construction and Expression of a Eukaryotic Expression Vector Containing a Fusion Gene of the Hantaan Virus S Gene and Hsp70 Gene.

Molecular insight into the neutralization mechanism of human-origin monoclonal antibody AH100 against Hantaan virus

A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of Hantaan virus induced protective immunity in mice

Construction and Expression of a Single-Chain HV Antibody-Protamine Fragment Fusion Protein 1A8 ScFv/Cκ/P

A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus

Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus

Targeted Inhibition of Hantavirus Replication and Intracranial Pathogenesis by a Chimeric Protein-Delivered Sirna.

Construction and Immunological Characterization of CD40L or GM-CSF Incorporated Hantaan Virus Like Particle

Identification of a novel B-cell epitope of Hantaan virus glycoprotein recognized by neutralizing 3D8 monoclonal antibody.

Hantavirus Gc Induces Long-Term Immune Protection Via LAMP-targeting DNA Vaccine Strategy.

Serologic Diagnosis of Hantaan Virus Infection Based on a Peptide Antigen

Antigenic characterization of expressed complete and different truncated recombinant nucleocapsid proteins of hantaan virus by monoclonal antibodies.

Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by <i>In Silico</i> Prediction and Experimental Validation

Screening and Identification of an H-2Kb-Restricted CTL Epitope Within the Glycoprotein of Hantaan Virus

Analysis of the Immune Response to Hantaan Virus Nucleocapsid Protein C-terminal-specific CD8(+) T Cells in Patients with Hemorrhagic Fever with Renal Syndrome.

Hantavirus-like Particles Generated in CHO Cells Induce Specific Immune Responses in C57BL/6 Mice